Oropharyngeal squamous cell carcinoma

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
5 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Kinase inhibitor 2 substances
Monoclonal antibody (immune) 1 substance
PARP inhibitor 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Fondazione GONO Plus Academic
    DOSTARLIMAB; NIRAPARIB
    2024-516798-54-00 1 country 2021 n=49
    Recruiting
  • Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Academic
    AFATINIB
    2024-511477-29-00 2 countries 2024 n=25 Orphan
    Recruiting
  • Universitaet Des Saarlandes Academic
    LENVATINIB; PEMBROLIZUMAB
    2024-516536-10-00 1 country 2023 n=50
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Fondazione GONO Plus Academic 1 Phase II 1
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Academic 1 Phase II 1
Universitaet Des Saarlandes Academic 1 Phase II 0
New trials by year
2021
1
2023
1
2024
1
← All indication landscapes